Effect Of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitors on Body Mass Index After 3 Months of Use in Diabetic Patients

Effect Of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitors on Body Mass Index After 3 Months of Use in Diabetic Patients"

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07367555

Enrollment

360

Registered

2026-01-26

Start date

2024-10-01

Completion date

2025-03-31

Last updated

2026-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabete Mellitus

Keywords

Body Mass Index, Glycemic Index, Sodium Glucose Co-transporter-2 Inhibitors

Brief summary

Total of 360 participants were enrolled and prescribed oral 200 mg SGLT-2 tablet. All participants were followed-up for about three months. Body mass index was measured before and after three months and mean change in BMI was assessed.

Interventions

DRUGOral 100 gram Empagliflozin tablet along with diet plan and exercise

oral 100 gram Empagliflozin tablet along with diet plan and exercise

OTHERDiet plan and exercise

Only Life style modification was advised. Changes in BMI were assessed.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

30 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Individuals diagnosed with type II diabetes mellitus ( blood sugar level (random) at presentation was above 186 mg/dl and HbA1c was more than 6.5% on laboratory investigations)

Exclusion criteria

* Individuals already taking trail drug or any other anti-glycemic drug or insulin for \>6 months

Design outcomes

Primary

Measure	Time frame	Description
Weight	03 Months	Weight is measured in Kilograms

Secondary

Measure	Time frame	Description
Height	03 months	Height is measured in meters

Countries

Pakistan

Contacts

STUDY_DIRECTORProfessor Dr Khalid Mehmood Raja, MBBS FCPS

CMH Multan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026